Craig Collard - Jul 1, 2022 Form 4 Insider Report for Sierra Oncology, Inc. (SRRA)

Role
Director
Signature
/s/ Craig A. Collard; By: Mary Christina Thomson, Attorney-In-Fact
Stock symbol
SRRA
Transactions as of
Jul 1, 2022
Transactions value $
-$742,500
Form type
4
Date filed
7/1/2022, 04:37 PM
Previous filing
Jun 29, 2022
Next filing
Sep 26, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRRA Common Stock Disposed to Issuer -$743K -13.5K -100% $55.00 0 Jul 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -10K -100% $0.00* 0 Jul 1, 2022 Common Stock 10K $13.88 Direct F1, F2
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -6K -100% $0.00* 0 Jul 1, 2022 Common Stock 6K $18.11 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Craig Collard is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The option fully vested on May 28, 2021.
F2 Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
F3 The option fully vested on June 8, 2022.